Toxicity of Synthetic Cannabinoids in K2/Spice: A Systematic Review

• Published in: Brain sciences 2023-06, Vol.13 (7), p.990
• Main Authors: de Oliveira, Mariana Campello, Vides, Mariana Capelo, Lassi, Dângela Layne Silva, Torales, Julio, Ventriglio, Antonio, Bombana, Henrique Silva, Leyton, Vilma, Périco, Cintia de Azevedo-Marques, Negrão, André Brooking, Malbergier, André, Castaldelli-Maia, João Maurício
• Format: Article
• Language: English
• Subjects: Addictions; Cannabinoids; Cannabis; Cardiac arrhythmia; Case reports; Case studies; Drug abuse; Drug development; Emergency medical care; Epilepsy; Fatalities; Females; Health aspects; Intoxication; Ischemia; JWH; Marijuana; Mental disorders; Nausea; Nervous system diseases; Phenols; Psychosis; Psychotropic drugs; RCS; Schizophrenia; Seizures; Spice; synthetic cannabinoid; Systematic Review; Tachycardia; Tetrahydrocannabinol; THC; Toxicity
• ISSN: 2076-3425; 2076-3425
• DOI: 10.3390/brainsci13070990

(1) Background: Synthetic cannabinoids (SCs) are emerging drugs of abuse sold as 'K2', 'K9' or 'Spice'. Evidence shows that using SCs products leads to greater health risks than cannabis. They have been associated with greater toxicity and higher addiction potential unrelated to the primary psychoactive component of marijuana, Δ9-tetrahydrocannabinol (Δ9-THC). Moreover, early cases of intoxication and death related to SCs highlight the inherent danger that may accompany the use of these substances. However, there is limited knowledge of the toxicology of Spice ingredients. This systematic review intends to analyze the toxicity of SCs compounds in Spice/K2 drugs. (2) Methods: Studies analyzing synthetic cannabinoid toxicity and dependence were included in the present review. We searched the PubMed database of the US National Library of Medicine, Google Scholar, CompTox Chemicals, and Web of Science up to May 2022. (3) Results: Sixty-four articles reporting the effects of synthetic cannabinoids in humans were included in our review. Ten original papers and fifty-four case studies were also included. Fourteen studies reported death associated with synthetic cannabinoid use, with AB-CHMINACA and MDMB-CHMICA being the main reported SCs. Tachycardia and seizures were the most common toxicity symptoms. The prevalence of neuropsychiatric symptoms was higher in third-generation SCs. (4) Conclusion: SCs may exhibit higher toxicity than THC and longer-lasting effects. Their use may be harmful, especially in people with epilepsy and schizophrenia, because of the increased risk of the precipitation of psychiatric and neurologic disorders. Compared to other drugs, SCs have a higher potential to trigger a convulsive crisis, a decline in consciousness, and hemodynamic changes. Therefore, it is crucial to clarify their potential harms and increase the availability of toxicology data in both clinical and research settings.